Dystrophin · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Dystrophin shows approved-linked disease relevance led by Becker muscular dystrophy. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P11532. Start with Becker muscular dystrophy, then reuse UniProt P11532 as the stable protein anchor across project notes and exports.
Start with Becker muscular dystrophy, then reuse UniProt P11532 as the stable protein anchor across project notes and exports.
Dystrophin shows approved-linked disease relevance led by Becker muscular dystrophy. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Becker muscular dystrophy because it currently carries approved-linked support. Linked drugs include DELANDISTROGENE MOXEPARVOVEC. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDystrophin
Review this target as Dystrophin, mapped to UniProt P11532. Sequence length is 3685 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dystrophin as ChEMBL target CHEMBL5498504, mapped to UniProt P11532. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Dystrophin is the right protein anchor across sources, using UniProt P11532 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Becker muscular dystrophy is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Dystrophin |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P11532 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Dystrophin |
| UniProt Accession | P11532 |
| Component Type | Protein |
| Sequence Length | 3685 aa |
Dystrophin
Review this target as Dystrophin, mapped to UniProt P11532. Sequence length is 3685 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Dystrophin shows approved-linked disease relevance led by Becker muscular dystrophy. 1 more disease program remain visible in the same review block.
Start review with Becker muscular dystrophy because it currently carries approved-linked support. Linked drugs include DELANDISTROGENE MOXEPARVOVEC. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.